To date, potential targets to prevent the progression of NAFLD have been selected, including molecules that express on the immune system cell surface, and the PD-1/PD-L1 complex is receiving attention (36). The gene discussed is CD274; the disease is metabolic dysfunction-associated steatotic liver disease.